ARES vs RPRX
ARES: A $622 billion alternative asset manager operating four complementary investment groups across credit, private equity, real assets, and secondaries with a disciplined, collaborative platform and strong institutional and retail distribution channels. RPRX: Royalty Pharma is the leading financier of pharmaceutical innovation, providing capital in exchange for long-term royalty streams on top-tier commercial drug therapies.
Side-by-side fundamentals
| Metric | ARES | RPRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $119.57 | $58.72 | |
| Market cap as of 2026-07-23 | $26.5B | $33.8B | |
| P/E as of 2026-07-23 | 42.55 | 40.88 | RPRX lower |
| PEG as of 2026-07-23 | 2.85 | 3.37 | ARES lower |
| Net margin as of 2026-07-23 | +10.5% | +33.9% | RPRX higher |
| Operating margin as of 2026-07-23 | +17.7% | +65.1% | RPRX higher |
| ROE as of 2026-07-23 | +14.5% | +12.7% | ARES higher |
| ROA as of 2026-07-23 | +2.2% | +4.3% | RPRX higher |
| Debt / equity as of 2026-07-23 | 3.33 | 1.30 | RPRX lower |
| Revenue growth (YoY) as of 2026-07-23 | +38.5% | +7.8% | ARES higher |
| Revenue CAGR (3y) SEC XBRL | +18.2% | +2.1% | ARES higher |
| Dividend yield as of 2026-07-23 | +4.5% | +1.6% | ARES higher |
| Dividend streak (yrs) SEC XBRL | 4 | 5 | RPRX higher |
| Beta as of 2026-07-23 | 1.54 | 0.43 | |
| 1-year return as of 2026-07-22 close | -32.9% | +62.7% | RPRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.